MARKET

DCPH

DCPH

Deciphera Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.71
-1.45
-2.49%
After Hours: 56.71 0 0.00% 16:00 07/02 EDT
OPEN
58.60
PREV CLOSE
58.16
HIGH
58.64
LOW
55.42
VOLUME
327.33K
TURNOVER
--
52 WEEK HIGH
71.11
52 WEEK LOW
19.88
MARKET CAP
3.17B
P/E (TTM)
-12.5665
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DCPH stock price target is 72.50 with a high estimate of 91.00 and a low estimate of 55.00.

EPS

DCPH News

More
Deciphera Highlights Presentation Of Analysis Of Crossover Population From INVICTUS Phase 3 Study Of QINLOCK (ripretinib) In Patients With Fourth-Line Advanced GIST
-  Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - WALTHAM,
 Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - WALTHAM, · 1d ago
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who crossed over to QINLOCK therapy following disease progression
Business Wire · 1d ago
Deciphera Announces Health Canadas Authorization of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Business Wire · 06/22 12:00
Deciphera Announces Health Canada Authorization of QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Benzinga · 06/22 11:20
3 Strong Buy Healthcare Stocks That Should Remain Healthy
TipRanks · 06/18 00:36
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
Business Wire · 06/11 12:00
Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK (ripretinib) in The Lancet Oncology
Business Wire · 06/08 12:30
Hedge Funds Have Never Been More Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Monkey · 06/08 07:56

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About DCPH

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
More

Webull offers kinds of Deciphera Pharmaceuticals Inc stock information, including NASDAQ:DCPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCPH stock methods without spending real money on the virtual paper trading platform.